{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:54:04Z","timestamp":1763330044395,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>This study aimed to compare treatment satisfaction with two dosing regimens (two teriparatide [TPTD] self-injection systems) in osteoporosis patients at high risk of fracture.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>In this open-label crossover randomized trial comparing self-injected once-daily (1\/D)-TPTD with self-injected twice-weekly (2\/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2\u00a0years. The primary endpoint was overall satisfaction and secondary endpoints were satisfaction with treatment effectiveness and with utility of the self-injection device. Changes in quality of life (QOL) assessed by EuroQol-5 Dimension, pain assessed by visual analogue scale (VAS), and anthropometric parameters were also analyzed. Safety was evaluated based on the incidence and severity of adverse events (AEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 1\/D-TPTD and 2\/W-TPTD groups consisted of 180 (75.9\u2009\u00b1\u20097.3\u00a0years) and 179 (age: 75.5\u2009\u00b1\u20096.9\u00a0years) patients, respectively. After 26\u00a0weeks of treatment, no significant between-group difference in the persistence rate (79.4% vs 72.6% in the 1\/D-TPTD and 2\/W-TPTD groups, respectively), distributions of overall satisfaction scores, and satisfaction with treatment (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) were observed. However, several items of\u00a0satisfaction with the utility of the injection device were significantly higher in the 2\/W-TPTD group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Statistical improvements from baseline values were observed in QOL and pain VAS in both groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). No serious AEs were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The between-group similarity of overall treatment satisfaction and effectiveness scores and between-group difference in satisfaction with the utility of the self-injection device was useful information for real-world treatment of osteoporosis. Both medication regimens were well tolerated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00774-024-01521-7","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T09:05:35Z","timestamp":1718096735000},"page":"582-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06)"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-2747","authenticated-orcid":false,"given":"Satoshi","family":"Soen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"1521_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364\u2013376. https:\/\/doi.org\/10.1016\/S0140-6736(18)32112-3","journal-title":"Lancet"},{"key":"1521_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399:1080\u20131092. https:\/\/doi.org\/10.1016\/S0140-6736(21)02646-5","journal-title":"Lancet"},{"key":"1521_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/00325481.2022.2069582","volume":"134","author":"MR McClung","year":"2022","unstructured":"McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL (2022) The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med 134:541\u2013551. https:\/\/doi.org\/10.1080\/00325481.2022.2069582","journal-title":"Postgrad Med"},{"key":"1521_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4158\/EP-2019-0596","volume":"26","author":"F Cosman","year":"2020","unstructured":"Cosman F (2020) Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture. Endocr Pract 26:777\u2013786. https:\/\/doi.org\/10.4158\/EP-2019-0596","journal-title":"Endocr Pract"},{"key":"1521_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1586\/erp.10.76","volume":"10","author":"V Rabenda","year":"2010","unstructured":"Rabenda V, Reginster JY (2010) Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res 10:677\u2013689. https:\/\/doi.org\/10.1586\/erp.10.76","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1521_CR6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42115","author":"MM Alahmari","year":"2023","unstructured":"Alahmari MM, AlHilali AI, Thabet TA, Alshahrani MA, Mobasher WA, Al Mubarak DA, Alshamrani AM, Gohman RS, Alqarni SA, Alqahtani MM (2023) Impact of medication adherence on bone mineral density and fracture risk in patients with osteoporosis: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.42115","journal-title":"Cureus"},{"key":"1521_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1055\/a-1062-9447","volume":"51","author":"Q Chen","year":"2019","unstructured":"Chen Q, Guo M, Ma X, Pu Y, Long Y, Xu Y (2019) Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis. Horm Metab Res 51:785\u2013791. https:\/\/doi.org\/10.1055\/a-1062-9447","journal-title":"Horm Metab Res"},{"key":"1521_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12891-017-1514-4","volume":"18","author":"JH Park","year":"2017","unstructured":"Park JH, Park EK, Koo DW, Lee S, Lee SH, Kim GT, Lee SG (2017) Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis. BMC Musculoskelet Disord 18:152. https:\/\/doi.org\/10.1186\/s12891-017-1514-4","journal-title":"BMC Musculoskelet Disord"},{"key":"1521_CR9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"1521_CR10","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106. https:\/\/doi.org\/10.1210\/jc.2011-3479","journal-title":"J Clin Endocrinol Metab"},{"key":"1521_CR11","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00198-019-05111-6","volume":"30","author":"T Sugimoto","year":"2019","unstructured":"Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T (2019) Study of twice-weekly injections of teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int 30:2321\u20132331. https:\/\/doi.org\/10.1007\/s00198-019-05111-6","journal-title":"Osteoporos Int"},{"key":"1521_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00774-022-01347-1","volume":"40","author":"R Fujita","year":"2022","unstructured":"Fujita R, Endo T, Takahata M, Haraya K, Suzuki H, Oda I, Kanayama M, Asano T, Shigenobu K, Iwata A, Yamada K, Takeuchi H, Ohura H, Yoneoka D, Iwasaki N (2022) Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis. J Bone Miner Metab 40:782\u2013789. https:\/\/doi.org\/10.1007\/s00774-022-01347-1","journal-title":"J Bone Miner Metab"},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpdd.687","volume":"9","author":"Y Kumagai","year":"2020","unstructured":"Kumagai Y, Ose A, Tanaka K, Sugimoto T (2020) Safety profiles, pharmacokinetics, and changes in bone turnover markers after twice-weekly subcutaneous administration of teriparatide in healthy Japanese postmenopausal women: a single-blind randomized study. Clin Pharmacol Drug Dev 9:87\u201396. https:\/\/doi.org\/10.1002\/cpdd.687","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1521_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S, Investigators DAPS (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725\u20131735. https:\/\/doi.org\/10.1007\/s00198-010-1378-z","journal-title":"Osteoporos Int"},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, Investigators DAPS (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos Int"},{"key":"1521_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto ST, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257. https:\/\/doi.org\/10.1007\/s00774-013-0447-8","journal-title":"J Bone Miner Metab"},{"key":"1521_CR17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"1521_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10457","author":"DT Gold","year":"2021","unstructured":"Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA (2021) Abaloparatide real world patient experience study. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10457","journal-title":"JBMR Plus"},{"key":"1521_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11657-018-0466-0","volume":"13","author":"T Usui","year":"2018","unstructured":"Usui T, Funagoshi M, Seto K, Ide K, Tanaka S, Kawakami K (2018) Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis. Arch Osteoporos 13:54. https:\/\/doi.org\/10.1007\/s11657-018-0466-0","journal-title":"Arch Osteoporos"},{"key":"1521_CR20","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00198-019-05052-0","volume":"30","author":"MA van Maren","year":"2019","unstructured":"van Maren MA, Wyers CE, Driessen JHM, Visser JV, De Vries F, van de Wijdeven K, Gevers S, Lems WF, Emmelot-Vonk MH, van den Bergh JP (2019) Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporosis Int 30:1837\u20131844. https:\/\/doi.org\/10.1007\/s00198-019-05052-0","journal-title":"Osteoporosis Int"},{"key":"1521_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11657-018-0487-8","volume":"13","author":"M Sato","year":"2018","unstructured":"Sato M, Tsujimoto M, Kajimoto K, Uetake H, Shimoda H, Fujiwara S (2018) Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS). Arch Osteoporos 13:74. https:\/\/doi.org\/10.1007\/s11657-018-0487-8","journal-title":"Arch Osteoporos"},{"key":"1521_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jbspin.2013.05.001","volume":"81","author":"G Rajzbaum","year":"2014","unstructured":"Rajzbaum G, Grados F, Evans D, Liu-Leage S, Petto H, Augendre-Ferrante B (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study. Joint Bone Spine 81:69\u201375. https:\/\/doi.org\/10.1016\/j.jbspin.2013.05.001","journal-title":"Joint Bone Spine"},{"key":"1521_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1080\/03007995.2017.1354826","volume":"33","author":"S Soen","year":"2017","unstructured":"Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M, Kimura S, Sato M, Krege JH, Enomoto H (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Curr Med Res Opin 33:2049\u20132056. https:\/\/doi.org\/10.1080\/03007995.2017.1354826","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-024-01521-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T06:01:37Z","timestamp":1728194497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-024-01521-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s00774-024-01521-7","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Shiro Tanaka has received lecture fees from the Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Eli Lilly and Company, Welby, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Science and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. Y Takeuchi has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharma Co., Ltd., and Teijin Pharma Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Towa Pharmaceutical Co. Ltd. J Takada has received consulting fees and speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd. S Ikeda has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Pfizer Inc., Hisamitsu Pharmaceutical Co., Inc., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. J Iwamoto has received speaking fees from Asahi Kasei Pharma Corp., Eisai Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Teijin Pharma Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kaken Pharmaceutical Co., Ltd., Amgen Inc., Astellas Pharma Inc., Towa Pharmaceutical Co., Ltd. N Okimoto has received payments for lectures, including speakers' bureau fees from Asahi Kasei Pharma Corp., Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan, and Teijin Pharma Ltd. Sakae Tanaka has received lecture fees from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Amgen Inc., and Daiichi Sankyo Co., Ltd., and research grants from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Y Uemura and N Endo have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}